Kamada (KMDA) Q2 2026 Earnings Call Transcript
Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.
How this was made
The 30-second read
Why it matters
The disclosed financials exceed prior expectations, indicating continued organic growth and operational leverage.
Market read
First disclosure of Q2 results provides fresh data for traders; reinforces bullish case for KMDA.
What to watch
Potential supply‑chain risks in plasma collection and reliance on a single large plasma buyer.
Background
Kamada presented its Q2 2026 earnings, reporting record revenues and reaffirming full‑year guidance.
Ticker impact
Q2 2026 earnings call disclosed record revenues of $54.9M and adjusted EBITDA of $14.1M, plus reaffirmed 2026 guidance.
Potential price appreciation if market digests the beat and guidance reaffirmation.
First‑time disclosure of quarterly results with better‑than‑expected growth and solid cash generation.
Market effects
Highlights strength in specialty plasma‑derived therapeutics, may lift peers in the biotech plasma sector.
Positive for U.S. biotech and Israeli distribution markets where Kamada operates.
Modest; primarily relevant to investors focused on niche biotech and plasma product space.
Counterpoint
Growth may be unsustainable without the pending M&A; valuation could be stretched.
Key entities
- CompanyKamada Ltd.
Specialty plasma‑derived therapeutics manufacturer.
